On September 9, 2019, Grünenthal, a global leader in pain management, and Mesoblast Limited, a world leader in allogeneic cellular medicines for inflammatory diseases, announced that they have entered into a strategic partnership to develop and commercialize MPC-06-ID, a Phase III allogeneic cell therapy candidate for the treatment of chronic low back pain due to degenerative disc disease in patients who have exhausted conservative treatment options. Under the partnership, Grünenthal will have exclusive commercialization rights to MPC-06-ID for Europe and Latin America. Wilson Sonsini Goodrich & Rosati represented Mesoblast in the transaction.

Mesoblast Chief Executive Dr Silviu Itescu stated: “We are very pleased to enter into this strategic partnership with Grünenthal, a world leader in innovative approaches to pain management. Together with Grünenthal we plan to bring an important new class of therapy for pain management to the many patients suffering with degenerative disc disease. This partnership is in line with our corporate strategy to team up with best in category commercial leaders to maximize market access for our innovative cellular medicines for the treatment of patients suffering from debilitating or life-threatening inflammatory conditions."

The WSGR team representing Mesoblast in the deal includes the following attorneys:

Techonology Transactions
Matt Wiltermuth, Partner
Ian Edvalson, Partner
Priya Merrill, Associate

For additional information, please see the press release announcing the agreement.